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Abstract 
Case 1: A 67-year-old Asian female was diagnosed with locally advanced high-grade salivary 
duct carcinoma in June 2011. Molecular analysis revealed human epidermal growth factor 
receptor 2 (HER-2) amplification. She received adjuvant therapy with carboplatin/paclitaxel/ 
trastuzumab and maintenance of trastuzumab. Upon disease progression, trastuzumab could 
not be continued due to lack of financial coverage. Instead, she was treated with compas-
sionate use of lapatinib from April 2013 and standard 5-fluorouracil. Her disease ultimately 
progressed and she expired later in 2013. Case 2: A 68-year-old Asian male was diagnosed 
with extramammary Paget’s disease of the scrotum with HER-2 amplification in May 2011. He 
received 6 cycles of adjuvant trastuzumab/docetaxel/carboplatin followed by maintenance 
trastuzumab, which was changed to compassionate use of lapatinib as his insurance did not 
cover further administration of trastuzumab. He showed clinical benefits from single-agent 
lapatinib and a combination of lapatinib/capecitabine upon progression to the single-agent 
lapatinib. Ultimately, he was started on ado-trastuzumab emtansine, which was approved at 
that time by the FDA for HER-2-positive breast cancer progressed on trastuzumab. He is 
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having clinical and radiographic complete response based on current imaging and normali-
zation of his tumor markers. Conclusion: HER-2-targeted therapy should be considered for 
tumors with HER-2 amplification. In our case series, we would like to emphasize this ap-
proach in other rare histologies. Specifically, our patient with extramammary Paget’s disease 
of the scrotum represents the first reported case of a non-breast, non-gastric tumor with 
HER-2 overexpression with complete clinical and radiographic response to HER-2-targeted 
therapy. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Background 
The discovery of the role of human epidermal growth factor receptor 2 (HER-2) in 
breast cancer research was the result of the observation of amplified HER-2 in breast cancer 
cell line models, prompting analysis of clinical breast cancer specimens. This translational 
breast cancer research effort was driven by its prevalence, public awareness and high level 
of interest leading to significant sources of funding and research focus in pursuing develop-
ment of effective therapies. The initial finding, published in 1987 [1], then identified a subset 
of breast cancer with the worst prognosis when compared with hormone-positive disease. In 
1998, the FDA approval of trastuzumab for metastatic HER-2-positive breast cancer and 
subsequent studies in earlier-stage disease as well as the development of further HER-2 
inhibitors [lapatinib, pertuzumab, ado-trastuzumab emtansine (T-DM1)] have now placed 
HER-2-positive breast cancer among those diseases with remarkably more favorable prog-
noses compared to hormone receptor-positive diseases. This experience as well as this case 
series of identifying HER-2 amplifications in rare tumors highlight the importance of the 
HER-2 amplification pathway, and how drugs like trastuzumab can be utilized in these dif-
ferent cancers with the HER-2 amplification. 
While one would expect that those treatments will be important for treatment of tumors 
overexpressing HER-2, based on the current oncology guidelines (NCCN, ASCO) this is not 
the standard of care and up until recently most FDA-approved therapies are based on histol-
ogy. With the novel approach in melanoma research, the scientific community is changing 
the clinical practice; however, most tumors are still being treated based on the underlying 
pathology. The problem with the approach of relying on histologic primary disease to define 
which patient population to study, is that it will inherently neglect uncommon or rare tu-
mors where accrual of adequate numbers of patients for these clinical trials would be next to 
impossible. 
Comprehensive molecular screening of tumors and target identification has been stud-
ied by Von Hoff et al. [2] utilizing the Caris platform with positive results supporting further 
study of this approach. Given this other groups/commercial diagnostics (theranostics), com-
panies have emerging technologies to further support this effort (Foundation One Medicine, 
Guardant 360, Biotheranostics, Inc., Cellnetix, etc.). However, despite the ability to screen 
tumors for a predictive biomarker such as amplified HER-2, to date, registrational studies 
based on molecular tumor data without respect to primary tumor type have been lacking; 
thus, FDA approval and insurance coverage for these patients is not routinely supported. 
The purpose of this report is to illustrate two cases of relatively uncommon or rare dis-
eases where a molecular screen surprisingly revealed a HER-2 amplification suggesting con-
sideration for HER-2-directed therapy. Those HER-2-positive cases are salivary duct carci-
noma (SDC) and extramammary Paget’s disease (EMPD) of the scrotum. 
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SDCs are highly aggressive tumors with poor 5-year survival and 20–25% of patients 
present with metastatic disease [3]. Molecular oncogenesis in salivary gland tumor has been 
reported in a number of studies [4] and the HER-2 expression and the association with clini-
cal outcome has been controversial [3]. Combination of taxanes and trastuzumab is associat-
ed with some responses. A phase II trastuzumab monotherapy trial [5] in metastatic salivary 
gland tumor was closed early due to the low rate of positivity of HER-2 overexpression; 
however, one patient received 40 cycles of trastuzumab with partial response. 
EMPD is a rare malignant skin tumor and mainly occurs on skin appendages, regions 
rich in apocrine glands such as scrotum, vulva and axilla. Approximately, 20% of patients 
have metastatic disease at presentation, which carries poor prognosis. Currently, there are 
essentially no reliably effective treatments available for advanced cases [6]. HER-2-positive 
EMPD is extremely rare with only a few case reports. It has been suggested that HER-2 re-
ceptor contributes to the intra-epidermal spread of Paget cells, cellular proliferation as well 
as migration [7]. Tanaka et al. [8] reported over 100 cases of EMPD, and found approximate-
ly 15% of them had HER-2 overexpression which correlated with biologically aggressive 
disease with a few cases of HER-2-positive EMPD, treated with trastuzumab with clinical 
benefit. However, this is the first reported case of a patient with metastatic EMPD of the 
scrotum who has complete response to HER-2-directed therapy with T-DM1. 
Case Presentation 
Case 1: Salivary Duct Carcinoma 
A 67-year-old Asian female presented with an enlarging mass near her left parotid gland 
in June 2011 which had grown until she sought medical attention 3 months after initially 
noticing the mass. She did not have any significant comorbidities. MRI in September 2011 
showed an ill-defined, deep 3.7 × 3 × 3 cm left parotid gland and enlarged left cervical lymph 
nodes measuring up to 2.2 cm. Following PET-CT showed numerous hypermetabolic nodes 
in the ipsilateral neck levels II–V; however, there was no clear evidence of metastasis. She 
underwent biopsy of the left parotid mass as well as lymph nodes, which revealed epithelial 
neoplasm of uncertain origin. She was evaluated by head and neck surgery at UCLA and was 
noted to have a firm 5-cm left parotid mass as well as paralysis of the left marginal mandibu-
lar nerve and involuntary spasm of the left orbicularis oris and orbicularis oculi muscles. The 
patient underwent left total parotidectomy (sacrificing facial nerve) and modified neck dis-
section from levels I–V with neurolysis and preservation of the spinal accessory nerve. 
Laboratory and Diagnostic Summary 
The pathology showed high-grade SDC, a 6.1-cm parotid mass in its greatest dimension, 
extending into extraparotid soft tissue with extensive perineural/intraneural invasion as 
well as lymphatic and vascular invasion. The surgical margins were negative. Two of two 
intraparotid lymph nodes were positive for metastatic SDC. Thirty-one of sixty-seven lymph 
nodes were positive for metastatic high-grade SDC with extranodal extension. The vertical 
segment of her facial nerve was involved with clear surgical margins. Immunohistochem-
istry was positive for CK7, AR, mammaglobin, GCDFP15, and HER-2 with 3+. CK5/6 was fo-
cally positive and CK20 was negative. Subsequent FISH for HER-2 gene amplification was 
positive (fig. 1; R/G ratio, the ratio of HER-2 signal to centromere 17 signal, was 8.7. Ratio 
defined as 0.6 to 1.6 is negative, greater than 2.2 is positive and between 1.6 and 2.2 is 
equivocal). 
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Management and Outcome 
She received adjuvant chemoradiation with carboplatin/paclitaxel/trastuzumab fol-
lowed by trastuzumab every 3 weeks from June 2012. Capecitabine was added in September 
2012 due to cutaneous disease that represented dermal metastasis on the neck. Repeat bi-
opsy of the lesion confirmed high-grade carcinoma and HER-2 testing showed increased R/G 
ratio to 13.0 compared to 8.7 from initial biopsy. She experienced hand-foot syndrome from 
capecitabine, which required a dose adjustment. She had initial improvement in erythema 
and pain of the cutaneous lesion but eventually progressed. Given this worsening cutaneous 
disease, her regimen switched to FOLFOX without response. Subsequently, she received 
concomitant radiation treatment, followed by HER-2-directed therapy with trastuzumab and 
lapatinib, an oral tyrosine kinase inhibitor that interrupts HER-2 and epidermal growth fac-
tor receptor pathways. Unfortunately, trastuzumab administration was not continued due to 
lack of financial coverage from April 2013. Her disease eventually progressed and she ex-
pired in late 2013. 
Case 2: Extramammary Paget’s Disease of the Scrotum  
A 68-year-old Asian male was referred to UCLA for chronic skin condition on his penile, 
scrotal area, for which he received multiple antibiotic treatments. Eventually, he underwent 
a skin biopsy by a dermatologist that demonstrated EMPD of the scrotum. 
Laboratory and Diagnostic Summary. The patient underwent surgical excision on March 
2011. Staging CT scan did not reveal any adenopathy, although it showed 2 pulmonary  
micronodules. Fig. 2 shows the pathologic confirmation of HER-2 amplification. 
Management and Outcome. The patient presented a year later with local recurrence 
manifested as inguinal adenopathy. He underwent CT-guided biopsy that showed adenocar-
cinoma, which was consistent with EMPD originating from the scrotum. Additional molecu-
lar study revealed HER-2 positivity via FISH testing and the CT scan was negative for distant 
metastatic disease. He then underwent left radical superficial and deep inguinal node dissec-
tion as well as bilateral pelvic node dissection in July 2012. He received 6 cycles of adjuvant 
trastuzumab, docetaxel, and carboplatin completed by December 2012 followed by mainte-
nance trastuzumab. His insurance stopped covering trastuzumab and therefore, treatment 
was discontinued. During that time, his disease appeared to be progressing based on in-
creasing retroperitoneal lymphadenopathy. He underwent repeat biopsy of the lymph nodes 
confirming EMPD. Interestingly, his malignancy responded to reintroduction of HER-2-
targeted therapy with lapatinib. He remained on this single-agent treatment for several 
months; however, his course was complicated by liver function test abnormalities. Capecita-
bine was added due to inability to maintain full dosing of lapatinib as well as progressive 
disease in restaging PET-CT. Upon progression, he was started on T-DM1. At the time of this 
report, he has been in active treatment for almost a year and he continues to have radiologic 
complete response. 
Discussion 
It was a breakthrough discovery by Dr. Dennis Slamon’s research group in the 1980s 
that HER-2 gene amplification/overexpression was linked to more aggressive breast cancer. 
The identification of the HER-2 pathway led to the era of ‘targeted therapy’ in cancer man-
agement [1]. Trastuzumab was approved in 1998 based on unprecedented clinical activity 
among 20–25% of a subset of breast cancer patients who had HER-2 amplifica-
tion/overexpression [9]. HER-2-directed therapy had been mainly used for breast cancer 
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patients up until the TOGA trial showed the clinical activity on 10–15% of patients with  
metastatic gastric cancer that have HER-2 amplification/overexpression [10]. HER-2 ampli-
fication/overexpression on other epithelial malignancies such as bladder, colon and lung has 
been identified, although the clinical activity of trastuzumab is not as impressive as shown 
with breast cancer [11]. Recent reports suggested that HER-2 expression is not associated 
with colon cancer prognosis [12]; however, HER-2-targeted therapeutic application for these 
cancers are still ongoing, especially with dual targeted strategies for colon cancer as we 
learned from breast cancer studies [13]. In this case series, we would like to highlight the 
importance of identification of HER-2 amplification/overexpression in uncommon types  
of epithelial malignancies with the development of molecular profiling as well as next-gen-
eration sequencing techniques [14]. 
In this case series, we reported two rare HER-2-amplified epithelial malignancies: sali-
vary ductal adenocarcinoma, EMPD, and HPV-positive oral cavity squamous cell carcinoma. 
Given the rarity or scarcity of these cases, it is less feasible to conduct clinical trials based on 
primary histology to show the potential benefit of HER-2-directed therapy, which is required 
for FDA approval. Although those two patients were recommended for HER-2-directed ther-
apy, their course of treatment was interrupted by lack of insurance coverage. It may be 
worth considering a discussion in another context about the possible ethical issues raised by 
the limitation of their access to the best available therapy. 
Conclusion 
The HER-2 signaling pathway is ubiquitously expressed in epithelia and aberrant ex-
pression increasingly identified in a subset of many epithelial cancers, certainly not unique 
to breast or gastric tumors. The experience that was obtained from the trastuzumab use in 
breast cancer suggests that treatment should be based on the biomarker status (with the 
main example being the HER-2 status). It is very important for the medical and scientific 
community but most importantly for the third party payers to recognize that those rare tu-
mors could still be managed with already FDA-approved drugs for other indications. The 
field should evolve and treatment should also consider the molecular background of those 
tumors rather than the organ that the tumor is originating from. 
Statement of Ethics 
Written informed consents were obtained from the patients for publication of this case 
series and any accompanying images. The copies of the written consents are available for 
review by the Editor-in-Chief of this journal. 
Disclosure Statement 
The authors declare no competing interests. 
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Fig. 1. Case 1, left parotid mass: HER-2 immunohistochemistry demonstrates overexpression at ×100 (a) 
magnification and ×400 (b) magnification. 
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Fig. 2. Case 2, scrotal biopsy: a HER-2 immunohistochemistry demonstrates overexpression at ×400 mag-
nification; b fluorescence in situ hybridization analysis demonstrates HER-2 amplification. 
 
